Brief: Ziccum Presents Results From Evaluation Study Analyzing LaminarPace

Ziccum AB

23/09/2022 14:17

Sept 23 (Reuters) - Ziccum AB  ZICC.ST :
    * RECEIVES RESULTS FROM EVALUATION STUDY ANALYZING LAMINARPACE WITH LEADING PHARMACEUTICAL
CORPORATION 
    * DATA DEMONSTRATED EXCELLENT RESULTS ON THERMOSTABILITY, POSITIVE RESULTS ON PARTICLE
APPEARANCE
    * BUT DATA ALSO DEMONSTRATED  SIGNIFICANT LOSS OF INFECTIVITY, REQUIRING FURTHER DEVELOPMENT
    * CLIENT HAS PAUSED ASSESSMENT OF LAMINARPACETM ON CURRENT VACCINE PLATFORM, BUT WILL
CONSIDER
TECHNOLOGY IN REGARD TO OTHER VACCINE PLATFORMS, WHERE DRY FORMULATION COULD BE A HIGHER
PRIORITY

Source text for Eikon:  ID:nMFN92GVTR 
Further company coverage:  ZICC.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))